BDNF and myeloid sarcoma: Fluoxetine, a selective serotonin-reuptake inhibitor (SSRI), might be able to protect against axonal loss underlying the progressive phase of MS because it stimulates glycogenolysis and it enhances the production of brain-derived neurotrophic factor in rodent astrocyte cultures [12, 13].